Details for New Drug Application (NDA): 075828
✉ Email this page to a colleague
NDA 075828 describes LOVASTATIN, which is a drug marketed by Actavis Elizabeth, Aurobindo Pharma Usa, Carlsbad, Chartwell Rx, Corepharma, Epic Pharma Llc, Lupin, Sun Pharm Industries, and Teva, and is included in ten NDAs. It is available from twenty-two suppliers. Additional details are available on the LOVASTATIN profile page.
The generic ingredient in LOVASTATIN is lovastatin. There are thirty-three drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the lovastatin profile page.
The generic ingredient in LOVASTATIN is lovastatin. There are thirty-three drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the lovastatin profile page.
Summary for 075828
| Tradename: | LOVASTATIN |
| Applicant: | Actavis Elizabeth |
| Ingredient: | lovastatin |
| Patents: | 0 |
Pharmacology for NDA: 075828
| Mechanism of Action | Hydroxymethylglutaryl-CoA Reductase Inhibitors |
Medical Subject Heading (MeSH) Categories for 075828
Suppliers and Packaging for NDA: 075828
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| LOVASTATIN | lovastatin | TABLET;ORAL | 075828 | ANDA | Aphena Pharma Solutions - Tennessee, LLC | 43353-995 | 43353-995-45 | 45 TABLET in 1 BOTTLE (43353-995-45) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 10MG | ||||
| Approval Date: | Dec 17, 2001 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 20MG | ||||
| Approval Date: | Dec 17, 2001 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 40MG | ||||
| Approval Date: | Dec 17, 2001 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
